Hologic (NASDAQ:HOLX) Price Target Raised to $91.00 at JPMorgan Chase & Co.

Hologic (NASDAQ:HOLX) had its target price boosted by JPMorgan Chase & Co. from $85.00 to $91.00 in a research report sent to investors on Friday morning, Benzinga reports. The brokerage currently has an overweight rating on the medical equipment provider’s stock.

Other analysts also recently issued research reports about the stock. Evercore ISI increased their price objective on shares of Hologic from $76.00 to $78.00 and gave the company an in-line rating in a research report on Thursday, April 4th. William Blair reiterated an outperform rating on shares of Hologic in a report on Friday, February 2nd. StockNews.com downgraded Hologic from a buy rating to a hold rating in a research note on Friday, March 8th. Raymond James lifted their target price on Hologic from $85.00 to $88.00 and gave the stock an outperform rating in a research report on Friday, February 2nd. Finally, Needham & Company LLC restated a buy rating and set a $90.00 price objective on shares of Hologic in a research note on Friday. Five analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Hologic currently has a consensus rating of Moderate Buy and a consensus price target of $84.56.

Hologic Trading Up 0.8 %

HOLX traded up $0.63 during trading on Friday, hitting $76.54. 2,069,424 shares of the company’s stock were exchanged, compared to its average volume of 1,449,410. Hologic has a 1 year low of $64.02 and a 1 year high of $86.74. The stock has a 50 day moving average price of $76.13 and a 200 day moving average price of $73.02. The firm has a market cap of $17.97 billion, a P/E ratio of 39.05, a price-to-earnings-growth ratio of 2.56 and a beta of 1.01. The company has a current ratio of 3.89, a quick ratio of 3.18 and a debt-to-equity ratio of 0.55.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.05. Hologic had a return on equity of 18.81% and a net margin of 11.78%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period in the prior year, the firm earned $1.06 EPS. The firm’s quarterly revenue was down .8% compared to the same quarter last year. As a group, analysts expect that Hologic will post 4.02 EPS for the current fiscal year.

Insider Activity

In other Hologic news, Director Scott T. Garrett sold 16,441 shares of the firm’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the transaction, the director now owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Charles J. Dockendorff sold 1,465 shares of the business’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the completion of the transaction, the director now owns 1,572 shares of the company’s stock, valued at $119,802.12. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Scott T. Garrett sold 16,441 shares of the stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the sale, the director now directly owns 48,611 shares in the company, valued at approximately $3,670,130.50. The disclosure for this sale can be found here. Company insiders own 1.75% of the company’s stock.

Institutional Investors Weigh In On Hologic

Several large investors have recently made changes to their positions in HOLX. McGlone Suttner Wealth Management Inc. bought a new position in Hologic in the 4th quarter worth approximately $27,000. Venturi Wealth Management LLC bought a new position in shares of Hologic in the third quarter worth $29,000. NBC Securities Inc. acquired a new position in shares of Hologic during the third quarter valued at $33,000. Deseret Mutual Benefit Administrators raised its stake in shares of Hologic by 42.2% during the third quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 155 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV lifted its holdings in Hologic by 69.4% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 227 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.